Amgen Out-Licenses its AMG 714 (PRO-015) Candidate to Provention to Treat Celiac Disease
Shots:
- Amgen to make $20M investment in Provention and also has option to license AMG-714 (after completion of P-IIb)- if exercised will pay $150M as upfront plus milestones and royalties to Provention
- Provention to fund and conduct the P-IIb trial for PRO-015 (AMG 714) and holds commercialization rights (if not exercised by Amgen) while giving $55M as upfront and milestone to Amgen
- AMG 714 (PRV-015) is a mAb that binds to IL-15- indicated for the treatment of Celiac Disease
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
